EUVIMEDEUVIMED entdecken
Crossref

Isatin-pyrimidine hybrid derivatives as enoyl acyl carrier protein reductase (InhA) inhibitors against Mycobacterium tuberculosis

Abdalrahman Khalifa, Amira Khalil, Marwa M Abdel-Aziz, Amgad Albohy, Samy Mohamady

Bioorganic Chemistry · 2023

DOI: 10.1016/j.bioorg.2023.106591 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2023. Verfasst von Abdalrahman Khalifa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo 11837, Egypt; The Center for Dru…. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Isatin. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: British University in Egypt.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis is a worldwide problem that impose a burden on the economy due to continuous development of resistant strains. The development of new antitubercular drugs is a need and can be achieved through inhibition of druggable targets. Mycobacterium tuberculosis enoyl acyl carrier protein (ACP) reductase (InhA) is an important enzyme for Mycobacterium tuberculosis survival. In this study, we report the synthesis of isatin derivatives that could treat TB through inhibition of this enzyme. Compound 4l showed IC50 value (0.6 ± 0.94 µM) similar to isoniazid but is also effective against MDR and XDR Mycobacterium tuberculosis strains (MIC of 0.48 and 3.9 µg/mL, respectively). Molecular docking studies suggest that this compound binds through the use of relatively unexplored hydrophobic pocket in the active site. Molecular dynamics was used to investigate and support the stability of 4l complex with the target enzyme. This study paves the way for the design and synthesis of novel antitubercular drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisIsatinAcyl Carrier ProteinMolecular Docking SimulationOxidoreductasesAntitubercular AgentsPyrimidinesBacterial ProteinsMicrobial Sensitivity Tests

Stichwörter der Autor:innen

Enoyl acyl carrier protein (ACP) reductaseInhA inhibitorsIsatinMolecular dockingMolecular dynamicsMolecular hybridizationMycobacterium tuberculosisPyrimidine

Substanzen

Acyl Carrier ProteinIsatinOxidoreductasesAntitubercular AgentsPyrimidinesBacterial Proteins

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo 11837, Egypt; The Center for Drug Research and Development (CDRD), Faculty of Pharmacy, The British Un…
  • The Regional Center for Mycology & Biotechnology, Al-Azhar University, Cairo, Egypt.

Förderung

  • British University in Egypt

Zitieren

APA

Khalifa, A., Khalil, A., Abdel-Aziz, M. M., Albohy, A., & Mohamady, S. (2023). Isatin-pyrimidine hybrid derivatives as enoyl acyl carrier protein reductase (InhA) inhibitors against Mycobacterium tuberculosis. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2023.106591

Vancouver

Khalifa A, Khalil A, Abdel-Aziz MM, Albohy A, Mohamady S. Isatin-pyrimidine hybrid derivatives as enoyl acyl carrier protein reductase (InhA) inhibitors against Mycobacterium tuberculosis. Bioorganic Chemistry. 2023. doi:10.1016/j.bioorg.2023.106591

BibTeX
@article{Khalifa2023,
  author = {Khalifa, Abdalrahman and Khalil, Amira and Abdel-Aziz, Marwa M and Albohy, Amgad and Mohamady, Samy},
  title = {Isatin-pyrimidine hybrid derivatives as enoyl acyl carrier protein reductase (InhA) inhibitors against Mycobacterium tuberculosis},
  journal = {Bioorganic Chemistry},
  year = {2023},
  doi = {10.1016/j.bioorg.2023.106591}
}
Kostenlos starten →